CClinicalTrials.gg
Status unknownNCT01747226MR2012Updated Dec 11, 2012

Effect of Mouth Rinses in Oral Malodor

An interventional study of Fluoride rinse and Halita in Halitosis, sponsored by Universitaire Ziekenhuizen KU Leuven. Status unknown at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-12-11.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2012), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Bad breath or halitosis is caused by specific gases originating from the mouth or the expired air. In most cases the pathology lies within the mouth and in this case receives the name pathologic halitosis of oral cause or oral malodor. The aim of this study is to evaluate the immediate (masking) and long term (therapeutic) effect of commercially available mouth rinses in the treatment of oral malodor. For this volunteers with oral malodor detected by organoleptic evaluation and confirmed by the increase level of sulphur compounds in their breath (VSC) will be asked to use a designated mouthwash. The breath parameters will be assessed at baseline and 15' after the first rinse (15 ml, during 1 minute) and over night at the end of a period of 3 weeks during which the volunteers rinsed twice a day (15 ml, 1 minute) with the assigned mouthwash. The short and long term effect of a stannous fluoride/amine fluoride/zinc rinse; a chlorhexidine/cetylpyridinium chloride/zinc product and a negative control(fluoride rinse and/or water) will be compared.

02

Conditions studied

  • Halitosis

Browse trials for

Keywords

  • Oral malodor
  • Halitosis
  • Bad Breath
  • Mouth rinses
  • Mouthwashes
  • Amine fluoride/Stannous fluoride
  • Zinc ions
  • Chlorhexidine
03

In context

Halitosis

88 studies on the registry are indexed under Halitosis; 18 are open to participants now.

This study's planned enrollment of 96 is above the median of 45 across 75 interventional studies indexed under Halitosis.

Browse Halitosis studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 928 studies on the registry; 261 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Caucasian
  • Age ≥ 18 years
  • Organoleptic score of breath ≥ 2
  • VSC readings (sum of H2S and CH3SH by OralChroma) ≥ 120 ppb*
  • Intra-oral cause of bad breath
  • Non-smokers
  • Willing to participate and able to give written informed consent

Exclusion criteria

Exclusion Criteria:

  • Ongoing dental treatment or any other medical treatment of the oral cavity
  • Any known allergy to previously used oral hygiene products or any known allergy to any of the ingredients of the study products, which are used during the study
  • Any pathological change of the oral mucosa
  • Use of prohibited treatments / therapies and/or abuse of drugs, alcohol, etc
  • Pregnancy or breastfeeding
  • Active caries
  • Acute sinusitis
  • Severe oro-pharyngeal infections
  • On medications which can cause malodour
  • Reduced salivary flow due to pathological reasons (e.g. Sjögren syndrome)
  • Situation considered not compatible with the study according to the investigator's opinion; the latter includes: patients eating very spicy food, persons under homeopathic therapy, patients who used antibiotics during the 2 months before the study, patients frequently using chewing gum, patients under corticosteroids or other serious medications.
  • Patients unwilling to abstain from additional oral hygiene (only toothbrushing allowed) particularly mouthrinse, chewing gums, breath strips, etc
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Placebo comparator
    Fluoride rinse

    A fluoride rinse with alcohol was chosen because its similarity in color and aroma to the active rinses. This anti-cavity rinse does not contain any active components and therefore it is not expected to have any anti-malodour activity.

    Other: Fluoride rinse

  • Active comparator
    Halita

    Halita is a CHX-containing benchmark product that has proven to be clinically effective against halitosis (Roldan et al, 2003)

    Other: Halita

  • Active comparator
    Meridol Halitosis

    This study aims to confirm the effect of meridol®Halitosis(AmF/SnF2 and zinc) already observed in volunteers with morning bad breath (physiological)(Wigger-Alberti et al, 2010; Wilhelm et al, 2010)in patients with oral malodor (pathological).

    Other: Meridol Halitosis

  • Sham comparator
    Water

    To distinguish the masking effect caused by the formulations and the one caused by the rinsing itself.Only for short term evaluation (15') to not to compromise compliance of patients.

    Other: Water

Interventions

  • OtherFluoride rinse

    rinse with 15 ml for 1 minute

  • OtherHalita

    rinsing with 15 ml for 1 minute

    Also known as: - Halita mouthwash 500 ml. CN 323923.3, - Halita, Dentaid Spain

  • OtherMeridol Halitosis

    rinsing with 15 ml for 1 minute

    Also known as: name of product meridol® HALITOSIS mouthrinse, GABA product number:266831, PDM number: 3*21750, name of manufacturer:GABA International AG

  • OtherWater

    rinsing with 15ml for 1 minute

    Also known as: bottled water

06

What researchers measure

Primary outcomes

  1. Change from baseline organoleptic score of breath (OLS)

    A trained and calibrated "judge" sniffs the expired air of the volunteer and assesses whether it is unpleasant by using an intensity rating, normally from 0 to 5, with 0 = no odor present, 1 = barely noticeable odor, 2 = slight but clearly noticeable odor, 3 = moderate odor, 4 = strong offensive odor, and 5 = extremely foul odor (proposed by Rosenberg and McCulloch.

    Time frame: after15' and after 3 weeks

  2. Change from baseline in H2S and CH3SH level in breath

    A portable gas chromatograph (OralChroma™, Abilit Corporation, Kanagawa, Japan) will be used to measures the concentration of hydrogen sulphur (H2S) and methyl mercaptan (CH3SH) in mouth air. The device has been calibrated and validated for its use by the manufacturer.

    Time frame: after 15' and after 3 weeks

Secondary outcomes

  1. Change from baseline global level of volatile sulphur compounds (VSC)

    A portable device (Halimeter®, Interscan Corporation, model RH-17E, Chatsworth, USA)able to detect sulphur compounds in air will be used according to the manufacturer instructions

    Time frame: after 15' and after 3 weeks

  2. Change from baseline microbial load of saliva

    A sample of non-stimulated saliva will be collected into a sterile container and kept at 4°C till processing. To the standard culture of the samples (of aerobic and anaerobic incubation at 37°C) a molecular technique (qPCR)of bacterial detection will be added for periodontal pathogens (P. gingivalis, P intermedia, F. nucleatum and A. actinomycetemcomitans) and bacteria usually involved in oral malodour (S. moorei).

    Time frame: after 3 weeks

  3. Change from baseline microbial load of tongue coating

    Tongue coating will be collected by wiping a sterile swab 3 times over the dorsum of the tongue, in the area of the foramen caecum. Till analysis; the tip of the cotton swab will be kept in a vial containing 2ml of reduced transport fluid (RTF). To the standard culture of the samples (of aerobic and anaerobic incubation at 37°C) a molecular technique (qPCR)of bacterial detection will be added for periodontal pathogens (P. gingivalis, P intermedia, F. nucleatum and A. actinomycetemcomitans) and bacteria usually involved in oral malodour (S. moorei).

    Time frame: after 3 weeks

Other outcomes

  1. Patients' opinion

    Patients' opinion regarding product satisfaction will be scored on a VAS line (0 to 10). The questionnaire will include the following points:satisfaction, side effects, use, future use and effectiveness.

    Time frame: after 3 weeks

07

Study locations

1 site
  • Department of Periodontology, KULeuven
    Leuven, 3000, Belgium
    • Jesica Dadamio, Master Bioch · Contact · jesica.dadamio@med.kuleuven.be · +32 16 347282
    • Jesica Dadamio, Master Bioch · Sub investigator
    • Sophie De Geest, DDS · Sub investigator
    • Marc Quirynen, PhD, DDS · Principal investigator
08

References and documents

Publications

  • Quirynen M, Dadamio J, Van den Velde S, De Smit M, Dekeyser C, Van Tornout M, Vandekerckhove B. Characteristics of 2000 patients who visited a halitosis clinic. J Clin Periodontol. 2009 Nov;36(11):970-5. doi: 10.1111/j.1600-051X.2009.01478.x. Epub 2009 Oct 6. PubMed 19811581 ↗
  • Wilhelm D, Gysen K, Himmelmann A, Krause C, Wilhelm KP. Short-term effect of a new mouthrinse formulation on oral malodour after single use in vivo: a comparative, randomized, single-blind, parallel-group clinical study. J Breath Res. 2010 Sep;4(3):036002. doi: 10.1088/1752-7155/4/3/036002. Epub 2010 Aug 17. PubMed 21383479 ↗
  • Wigger-Alberti W, Gysen K, Axmann EM, Wilhelm KP. Efficacy of a new mouthrinse formulation on the reduction of oral malodour in vivo. A randomized, double-blind, placebo-controlled, 3 week clinical study. J Breath Res. 2010 Mar;4(1):017102. doi: 10.1088/1752-7155/4/1/017102. Epub 2009 Dec 18. Erratum In: J Breath Res. 2010 Jun;4(2):029101. PubMed 21386207 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01747226
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Gaba International AG
Responsible party
Marc Quirynen (PhD DDS, Universitaire Ziekenhuizen KU Leuven) — Principal investigator
First posted
Dec 11, 2012
Start date
Mar 2013
Primary completion
Mar 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Dec 11, 2012

Study contacts

Marc Quirynen, PhD, DDS
Contact
marcquirynen@med.kuleuven.be
+32 16 33 24 85
Marc Quirynen, PhD, DDS
principal investigator · Universitarie Ziekenhuis Leuven

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion